NYSE:DPLO - Diplomat Pharmacy Stock Price, Price Target & More

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

Diplomat Pharmacy Inc (NYSE:DPLO) released its quarterly earnings results on Monday, May, 7th. The company reported $0.20 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.21 by $0.01. The business had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.28 billion. Diplomat Pharmacy had a net margin of 0.23% and a return on equity of 8.80%. The business's quarterly revenue was up 24.4% on a year-over-year basis. During the same period last year, the firm posted $0.19 EPS. View Diplomat Pharmacy's Earnings History.

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Diplomat Pharmacy.

Diplomat Pharmacy updated its FY18 earnings guidance on Monday, May, 7th. The company provided earnings per share guidance of $0.87-$0.97 for the period, compared to the Thomson Reuters consensus estimate of $0.92. The company issued revenue guidance of $5.5-$5.9 billion, compared to the consensus revenue estimate of $5.44 billion.

11 brokers have issued 1 year price objectives for Diplomat Pharmacy's shares. Their forecasts range from $18.00 to $35.00. On average, they anticipate Diplomat Pharmacy's share price to reach $26.90 in the next twelve months. This suggests a possible upside of 3.9% from the stock's current price. View Analyst Ratings for Diplomat Pharmacy.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Diplomat Pharmacy include Rite Aid (RAD), Petmed Express (PETS), Taxus Pharmaceuticals (TXSP), HealthWarehouse.com (HEWA) and Dougherty's Pharmacy (MYDP).

News articles about DPLO stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Diplomat Pharmacy earned a news impact score of 0.06 on Accern's scale. They also assigned news headlines about the company an impact score of 46.51 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Diplomat Pharmacy's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Columbia Partners L L C Investment Management (0.10%), Campbell & CO Investment Adviser LLC (0.01%), Fox Run Management L.L.C. (0.01%), Xact Kapitalforvaltning AB (0.01%) and Bank of Montreal Can (0.01%). Company insiders that own Diplomat Pharmacy stock include Atheer A Kaddis, Atul Kavthekar, Jeffrey G Park, Joel Saban, Philip R Hagerman and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

DPLO stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Jeffrey G Park, Philip R Hagerman and Shawn Tomasello. View Insider Buying and Selling for Diplomat Pharmacy.

DPLO stock was bought by a variety of institutional investors in the last quarter, including Columbia Partners L L C Investment Management, Campbell & CO Investment Adviser LLC, Fox Run Management L.L.C. and Xact Kapitalforvaltning AB. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DPLO stock can currently be purchased for approximately $25.89.

Diplomat Pharmacy has a market capitalization of $1.95 billion and generates $4.49 billion in revenue each year. The company earns $15.51 million in net income (profit) each year or $0.84 on an earnings per share basis. Diplomat Pharmacy employs 2,419 workers across the globe.

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]